Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | SHBG | P04278 | 3/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | STS | P08842 | 3/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SNCA | P37840 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18350076 | 0.85 | ESR1 (0.50) | ESR1ESR2CYP19A1DRD2DRD3 | |
| SCHEMBL18408045 | 0.85 | ESR1 (0.50) | ESR1ESR2CYP19A1DRD2DRD3 | |
| SCHEMBL13487602 | 0.81 | HTR2C (0.50) | SLC6A4HTR2B | |
| SCHEMBL683190 | 0.81 | SHBG (0.44) | ESR1ESR2SHBGDRD2DRD3 | |
| SCHEMBL8034552 | 0.81 | ESR1 (0.53) | ESR1ESR2CYP19A1SHBGDRD2 | |
| SCHEMBL13049833 | 0.81 | ESR1 (0.53) | ESR1ESR2CYP19A1SHBGDRD2 | |
| SCHEMBL16182360 | 0.80 | ESR1 (0.50) | ESR1ESR2CYP19A1SHBGDRD2 | |
| SCHEMBL9418187 | 0.80 | ESR1 (0.49) | ESR1ESR2CYP19A1 | |
| SCHEMBL13319529 | 0.80 | ESR1 (0.47) | ESR1ESR2CYP19A1SHBGHSD17B10 | |
| SCHEMBL9862638 | 0.80 | ESR1 (0.49) | ESR1ESR2CYP19A1SHBGHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11693316-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-11656549-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-05-23 | — | — | US | disclosed |
| US-11644751-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11644751-B2 | Resist composition and method of forming resist pattern | TOKYO OHKA KOGYO CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| WO-2020151633-A1 | PHARMACEUTICAL COMPOSITIONS | Shenzhen Pharmacin Co., Ltd. (CN) | 2020-07-30 | — | — | WO | disclosed |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | SHENZHEN PHARMACIN CO LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20180120705-A1 | PATTERN FORMING METHOD AND ELECTRONIC DEVICE MANUFACTURING METHOD | FUJIFILM CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-9766541-B2 | Positive-type resist composition, method for forming resist pattern, photo-reactive quencher, and polymeric compound | TOKYO OHKA KOGYO CO., LTD. (JP) | 2017-09-19 | — | — | US | disclosed |
| US-20120301817-A1 | ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, RESIST FILM USING THE COMPOSITION AND PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2012-11-29 | — | — | US | disclosed |
| US-20120231393-A1 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING A PATTERN USING THE SAME | FUJIFILM CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| US-20120082939-A1 | ACTIVE LIGHT RAY SENSITIVE OR RADIOACTIVE RAY SENSITIVE RESIN COMPOSITION, AND ACTIVE LIGHT RAY SENSITIVE OR RADIOACTIVE RAY SENSITIVE FILM AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2012-04-05 | — | — | US | disclosed |
| US-20120006788-A1 | CHEMICAL AMPLIFICATION RESIST COMPOSITION, AND MOLD PREPARATION METHOD AND RESIST FILM USING THE SAME | FUJIFILM CORPORATION (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20110318693-A1 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION, AND RESIST FILM AND PATTERN FORMING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110183263-A1 | ACTINIC-RAY- OR RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD OF FORMING PATTERN USING THE COMPOSITION | FUJIFILM CORPORATION (JP) | 2011-07-28 | — | — | US | disclosed |
| US-7875599-B2 | 3 beta -hydroxy-17-(1H-imidazole-1-yl)androsta-5,16-diene for treatment of prostate cancer; inhibitor of 17-alpha-hydroxylase/17,20 lyase/17,20 desmolase ( a cytochrome p-450 enzyme ) | UNIVERSITY OF MARYLAND (US) | 2011-01-25 | — | — | US | disclosed |
| EP-1853619-B1 | 3-BETA-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE FOR USE IN THE TREATMENT OF A PROSTATE DISEASE | UNIV MARYLAND (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100048912-A1 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2010-02-25 | — | — | US | disclosed |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | UNIVERSITY OF MARYLAND, BALTIMORE | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193095-A9 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | ESR1 4649/4885ESR2 4234/4885CYP19A1 674/4885 |
| US-20100048912-A1 | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, HSD17B7 | ESR1 217/4885ESR2 180/4885CYP19A1 9/4885 |
| US-20200237784-A1 | PHARMACEUTICAL COMPOSITIONS | LIPA, LIPC, MGLL | ESR1 4649/4885ESR2 4234/4885CYP19A1 674/4885 |
| US-20080280864-A1 | Novel C-17-Heteroaryl Steroidal Cyp17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity | CYP17A1, HSD17B1, CYP21A2 | ESR1 221/4885ESR2 182/4885CYP19A1 9/4885 |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | ESR1 656/4885ESR2 174/4885CYP19A1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.